An observational study in Diffuse Large B-cell Lymphoma, sponsored by Samsung Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 17 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-02-12.
Sponsored by Samsung Medical Center · Observational
The investigators analyzed clinical outcome in DLBCL patients according to age group to define the impact of EBV status on the clinical outcome.
Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) has been recognized as a new provisional entity in the 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue. This lymphoma is defined as EBV+ clonal B-cell proliferation in immunocompetent adults older than 50 years. To denote patient age in definition of this disease, age cutoff was defined as older than 50 years. However, this cutoff is clearly arbitrary without any scientific background. the knowledge on EBV+DLBCL in young adult is very scanty. This EBV+DLBCL in young adult can be the same disease entity or it can be a distinct disease form EBV+DLBCL of elderly.
159 studies on the registry are indexed under Epstein-Barr Virus Infections; 55 are open to participants now.
This study's enrollment of 571 is above the median of 140 across 43 observational studies indexed under Epstein-Barr Virus Infections.
Browse Epstein-Barr Virus Infections studies →Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
(1) pathologically confirmed de novo DLBCL, according to the World Health Organization (WHO) classification: (ii) registered in Samsung Medical Center (SMC) Lymphoma Cohort Study I/II (ClinicalTrials.gov Identifier: NCT00822731, NCT01877109) or identified from Asan Medical Center (AMC) medical database: (iii) adequate amount and quality of paraffin-embedded biopsy specimen or unstained slides for EBV-encoded RNA (EBER) in situ hybridization.
Pathologically confirmed de novo DLBCL, according to the World Health Organization (WHO) classification:
Exclusion Criteria:
EBV+DLBCL patients in Asan Medical Center
Other: EBER
EBV+DLBCL patients in Samsung Medical Center
Other: EBER
EBV-DLBCL patients in Samsung Medical Center
EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
overall survival
Time frame: Two years
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epstein-Barr Virus Infections→
Samsung Medical Center